The lentiviral vector system based on human immunodeficiency virus type 1 (HIV-1) is used extensively in gene therapy trials of neurological and neurodegenerative diseases. Retrograde axonal transport of viral vectors offers a great advantage to the delivery of genes into neuronal cell bodies that are situated in regions distant from the injection site. Pseudotyping of HIV-1-based vectors with selective variants of rabies virus glycoprotein (RV-G) increases gene transfer via retrograde transport into the central nervous system. Because large-scale application for gene therapy trials requires high titer stocks of the vector, pseudotyping of a lentiviral vector that produces more efficient retrograde transport is needed. In the present study, we developed a novel vector system for highly efficient retrograde gene transfer by pseudotyping an HIV-1 vector with a fusion envelope glycoprotein (termed FuG-B) in which the cytoplasmic domain of RV-G was substituted by the corresponding part of vesicular stomatitis virus glycoprotein. The FuG-B pseudotype shifted the transducing property of the lentiviral vector and enhanced the retrograde transport-mediated gene transfer into different brain regions innervating the striatum with greater efficiency than that of the RV-G pseudotype in mice. In addition, injection of the FuG-B-pseudotyped vector into monkey striatum (caudate and putamen) allowed for highly efficient gene delivery into the nigrostriatal dopamine system, which is a major target for gene therapy of Parkinson's disease. Our strategy provides a powerful tool for the treatment of certain neurological and neurodegenerative diseases by promoting retrograde gene delivery via a lentiviral vector.
Get full access to this article
View all access options for this article.
References
1.
AzzouzM., KingsmanS.M., MazarakisN.D.2004a. Lentiviral vectors for treating and modeling human CNS disorders. J. Gene Med., 6:951–962.
2.
AzzouzM., RalphG.S., StorkebaumE., WalmsleyL.E., MitrophanousK.A., KingsmanS.M., CarmelletP., MazarakisN.D.2004b. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature, 429:413–417.
3.
BarkatsM., HorellouP., ColinP., MillecampsS., Faucon-BiguetN., MalletJ.2006. 1-Methyl-4-phenylpyridinium neurotoxicity is attenuated by adenoviral gene transfer of human Cu/Zn superoxide dismutase. J. Neurosci. Res., 83:233–242.
4.
BaumgartnerB.J., ShineH.D.1998. Neuroprotection of spinal motoneurons following targeted transduction with an adenoviral vector carrying the gene for glial cell line-derived neurotrophic factor. Exp. Neurol., 153:102–112.
5.
BrogJ.S., SalyapongseA., DeutchA.Y., ZahmD.S.1993. The patterns of afferent innervations of the core and shell in the “accumbens” part of the rat ventral striatum: Immunohistochemical detection of retrogradely transported fluoro-gold. J. Comp. Neurol., 338:255–278.
6.
CossonP.1996. Direct interaction between the envelope and matrix proteins of HIV-1. EMBO J., 15:5783–5788.
7.
CroninJ., ZhangX.-Y., ReiserJ.2005. Altering the tropism of lentiviral vectors through pseudotyping. Curr. Gene Ther., 5:387–398.
Fjord-LarsenL., JohansenJ.L., KuskP., TornøeJ., GrønborgM, RosenbladC., WahlbergL.U.2005. Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct. Exp. Neurol., 195:49–60.
10.
GastjaM., HorvathJ., LentzT.L.1996. Rabies virus binding to the nicotinic acetylcholine receptor α subunit demonstrated by virus overlay protein binding assay. J. Gen. Virol., 77:2437–2440.
11.
GeorgievskaB., JakobssonJ., PerssonE., EricsonC., KirikD., LundbergC.2004. Regulated delivery of glial cell line-derived neurotrophic factor into rat striatum, using a tetracycline-dependent lentiviral vector. Hum. Gene Ther., 15:934–944.
12.
HanawaH., KellyP.F., NathwaniA.C., PersonsD.A., VandergriffJ.A., HargroveP., VaninE.F., NienhuisA.W.2002. Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. Mol. Ther., 5:242–251.
13.
HanawaH., HemattiP., KeyvanfarK., MetzgerM.E., KrouseA., DonahueR.E., KepesS., GrayJ., DunbarC.E., PersonsD.A., NienhuisA.W.2004. Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system. Blood, 103:4062–4069.
14.
HanhamC.A., ZhaoF., TignorG.H.1993. Evidence from the anti-idiotypic network that the acetylcholine receptor is a rabies virus receptor. J. Virol., 67:530–542.
15.
JeetendraE., RobinsonC.S., AlbrittonL.M., WhittM.A.2002. The membrane-proximal domain of vesicular stomatitis virus G protein functions as a membrane fusion potentiator and can induce hemifusion. J. Virol., 76:12300–12311.
16.
JohnsonJ.E., SchnellM.J., BuonocoreL., RoseJ.K.1997. Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins. J. Virol., 71:5060–5068.
17.
KatoS., InoueK., KobayashiK., YasoshimaY., MiyachiS., InoueS., HanawaH., ShimadaT., TakadaM., KobayashiK.2007. Efficient gene transfer via retrograde transport in rodent and primate brains using a human immunodeficiency virus type 1-based vector pseudotyped with rabies virus glycoprotein. Hum. Gene Ther., 18:1141–1151.
18.
KordowerJ.H., EmborgM.E., BlochJ., MaS.Y., ChuY., LeventhalL., McBrideJ., ChenE.-Y., PalfiS., RoitbergB.Z., BrownW.D., HoldenJ.E., PyzalskiR., TaylorM.D., CarveyP., LingZ., TronoD., HantrayeP., DéglonN., AebischerP.2000. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science, 290:767–773.
19.
Lo BiancoC., SchneiderB.L., BauerM., SajadiA., BriceA., IwatsuboT., AebischerP.2004. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an α-synuclein rat model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A., 101:17510–17515.
20.
LundbergC., BjörklundT., CarlssonT., JakobssonJ., HantrayeP., DéglonN., KirikD.2008. Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Curr. Gene Ther., 8:461–473.
21.
MazarakisN.D., AzzouzM., RohllJ.B., EllardF.M., WilkesF.J., OlsenA.L., CarterE.E., BarberR.D., BabanD.F., KingsmanS.M., KingsmanA.J., O'MalleyK., MitrophanousK.A.2001. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum. Mol. Genet., 10:2109–2121.
22.
McCoyM.K., RuhnK.A., MartinezT.N., McAlpineF.E., BleschA., TanseyM.G.2008. Intranigral lentiviral delivery of dopamine-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. Mol. Ther., 16:1572–1579.
23.
McIntyreD.C., KellyM.E., StainesW.A.1996. Efferent projections of the anterior perirhinal cortex in the rat. J. Comp. Neurol., 369:302–318.
24.
MentisG.Z., GravellM., HamiltonR., ShneiderN.A., O'DonovanM.J., SchubertM.2006. Transduction of motor neurons and muscle fibers by intramuscular injection of HIV-1-based vectors pseudotyped with select rabies virus glycoproteins. J. Neurosci. Methods, 157:208–217.
25.
MitrophanousK.A., YoonS., RohillJ.B., PatilD., WilkesF.J., KimV.N., KingsmanS.M., KingsmanA.J., MazarakisN.D.1999. Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther., 6:1808–1818.
26.
MochizukiH., SchwartzJ.P., TanakaK., BradyR.O., ReiserJ.1998. High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. J. Virol., 72:8873–8883.
27.
MorimotoK., HooperD.C., CarbaughH., FuZ.F., KoprowskiH., DietzscholdB.1998. Rabies virus quasispecies: Implications for pathogenesis. Proc. Natl. Acad. Sci. U.S.A., 95:3152–3156.
28.
NaldiniL., BlömerU., GageF.H., TronoD., VermaI.M.1996. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. U.S.A., 93:11382–11388.
29.
NiwaH., YamamuraK., MiyazakiJ.1991. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene, 108:193–199.
30.
OwensR.J., RoseJ.K.1993. Cytoplasmic domain requirement for incorporation of a foreign envelope protein into vesicular stomatitis virus. J. Virol., 67:360–365.
31.
PaxinosG., FranklinK.B.J.2001. The Mouse Brain in Stereotaxic Coordinates, 2nd. Academic Press: San Diego.
32.
PerreletD., FerriA., MackenzieA.E., SmithG.M., KornelukR.G., ListonP., SagotY., TerradoJ., MonnierD., KatoA.C.2000. IAP family proteins delay motoneuron cell death in vivo. Eur. J. Neurosci., 12:2059–2067.
33.
ReiserJ., HarmisonG., Kluepfel-StahlS., BradyR.O., KarlssonS., SchubertM.1996. Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc. Natl. Acad. Sci. U.S.A., 93:15266–15271.
34.
RidetJ.L., BensadounJ.C., DéglonN., AebischerP., ZurnA.D.2006. Lentivirus-mediated expression of glutathione peroxidase: Neuroprotection in murine models of Parkinson's disease. Neurobiol. Dis., 21:29–34.
35.
RobisonC.S., WhittM.A.2000. The membrane-proximal stem region of vesicular stomatitis virus G protein confers efficient virus assembly. J. Virol., 74:2239–2246.
36.
RoseJ.K., DoolittleR.F., AnilionisA., CurtisP.J., WunnerW.H.1982. Homology between the glycoproteins of vesicular stomatitis virus and rabies virus. J. Virol., 43:361–364.
37.
SapruM.K., YatesJ.W., HoganS., JiangL., HalterJ., BohnM.C.2006. Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp. Neurol., 198:382–390.
38.
SchnellM.J., BuonocoreL., BoritzE., GhoshH.P., ChernishR., RoseJ.K.1998. Requirement for a non-specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus. EMBO J., 17:1289–1296.
39.
SimonsK., GaroffH.1980. The budding mechanisms of enveloped animal viruses. J. Gen. Virol., 50:1–21.
40.
StephensE.B., CompansR.W.1988. Assembly of animal viruses at cellular membranes. Annu. Rev. Microbiol., 42:489–516.
41.
SzaboJ., CowanW.M.1984. A stereotaxic atlas of the brain of the cynomolgus monkey (Macaca fascicularis)J. Comp. Neurol., 222:265–300.
42.
ThoulouzeM.-I., LafageM., SchachnerM., HartmannU., CremerH., LafonM.1998. The neural cell adhesion molecule is a receptor for rabies virus. J. Virol., 72:7181–7190.
43.
TuffereauC., BénéjeanJ., BlondelD., KiefferB., FlamandA.1998. Low-affinity nerve-growth factor receptor (P75NTR) can serve as a receptor for rabies virus. EMBO J., 17:7250–7259.
44.
VercammenL., Van der PerrenA., VaudanoE., GijsbersR., DebyserZ., Van den HauteC., BaekelandtV.2006. Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease. Mol. Ther., 14:716–723.
45.
VertesR.P.2004. Differential projections of the infralimbic and prelimbic cortex in the rat. Synapse, 51:32–58.
46.
WittM.A., ChongL., RoseJ.K.1989. Glycoprotein cytoplasmic domain sequences required for rescue of a vesicular stomatitis virus glycoprotein mutant. J. Virol., 63:3569–3578.
47.
WongL.F., GoodheadL., PratC., MitrophanousK.A., KingsmanS.M., MazarakisN.D.2006. Lentivirus-mediated gene transfer to the central nervous system: Therapeutic and research applications. Hum. Gene Ther., 17:1–9.
48.
ZhengJ.S., TangL.L., ZhengS.S., ZhanR.Y., ZhouY.Q., GoudreauJ., KaufmanD., ChenA.F.2005. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease. Brain Res. Mol. Brain Res., 134:155–161.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
